Log in to your Inderes Free account to see all free content on this page.
Create account

Revenio Group

16.16 EUR

-2.77 %

14,295 following
Corporate customer

REG1V

NASDAQ Helsinki

Medical Equipment & Services

Health Care

-2.77 %
-11.11 %
-22.68 %
-27.86 %
-33.91 %
-31.38 %
-58.98 %
-70.80 %
+750.53 %

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more
Market cap
431.17M EUR
Turnover
878.89K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Buy
Target price
Updated
12.02.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 12.02.2026

Latest extensive report

Released: 21.01.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.4.
2026

Interim report Q1'26

6.8.
2026

Interim report Q2'26

29.10.
2026

Interim report Q3'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Revenio Q4'25 preview: Valuation reaches historic lows
Research by
Juha Kinnunen

Revenio Q4'25 preview: Valuation reaches historic lows

Revenio's valuation has fallen to a historically low level, as the industry faces concerns, especially after Zeiss's grim profit warning. We consider the concerns regarding Revenio to be exaggerated and estimate the company's earnings to be firmly on an upward trend this year.

Revenio Group
Forum discussions
At least according to statistics, the French work more hours per week on average than Finns. ec.europa.eu – 30 May 24 How many hours per week do Europeans work? In 2023, the actual weekly working hours for people aged 20-64 in their main job, in the EU, averaged 36.1 hours. A closer...
4/15/2026, 4:46 AM
by Verneri Pulkkinen
77
I wonder if we’ll start seeing some insider buying from the executive management as well, now that great business is on the horizon and the valuation is knocking on seven-year lows. If they don’t buy now, it says a lot.
4/16/2026, 2:26 PM
by Syyntakeeton
42
France. Comfort-seeking. Croissants. Trade unions. A bottle of wine at lunch, at dinner a little more freely. Surely, in this case, too, it was necessary to promise that all employees working in France would transfer as old employees and that they would be given a 2-3 year guarantee...
4/14/2026, 3:38 PM
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
33
I’m not a Revenio owner, but I’ve been watching the stock slide out of the corner of my eye. For the owners’ sake, I would have hoped that Reve would have been the target of the acquisition itself. I once worked with the French in an M&A situation, and I certainly don’t envy the ...
4/15/2026, 4:48 AM
by TitoK
31
The long-awaited acquisition, which has been hinted at for a long time. As a long-term owner of Revenio, I awaited it calmly for three reasons: Previous track record: The Centervue acquisition, as already mentioned here, was handled from start to finish as a textbook example, thoughtfully...
4/14/2026, 12:54 PM
by Iiizi
26
@Juha_Kinnunen’s thoughts on the acquisition, also in video form. Largely a repetition of the same points: In the short term, it’s a slightly expensive acquisition. If synergies are realized and cross-selling, etc., succeeds, then the multiples already look significantly more moderate...
4/14/2026, 11:52 AM
by Jackwelshh
24
I don’t own Revenio shares myself, but I’ve been following the company for a while and am somewhat familiar with the opportunities and challenges related to transformative situations like this. I can confirm the same experience, including M&A and carve-out situations. It’s one thing...
4/15/2026, 7:21 AM
23
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.